ArticleMolecular neurobiology2025
Selective Receptor Modulation by Truncated Neuropeptide Y (3-36) Dissociates Vasoconstriction from Neuroprotection in Experimental Glaucoma.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bisphenol S-Induced Neurobehavioral Impairment Is Characterized by c-Jun Activation and Distinct Dysregulation of Nrf2 and BDNF in the Zebrafish Brain.Neurotoxicity research · 2026Article
- Vorinostat Rescues Cognitive Deficits in a Neuroinflammatory Mouse Model: A Study of Sex Differences and the Underlying TLR4/NF-κB Mechanism.Neurochemical research · 2026Article
- Combined Puerarin and Magnesium Acetyl Taurate Intervention Mitigates Autism-Like Pathology Through Glutamatergic and MAPK Pathway Regulation.Neurochemical research · 2026Article
- Sulforaphane-Mediated Multitarget Therapeutic Effects in Methylmercury-Induced ALS-Like Pathology: Comparative Analysis and Multifaceted Approach to Neuroprotection and Systemic Recovery.Molecular neurobiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropeptide Y (NPY) is a multifunctional peptide with neuroprotective properties, but its therapeutic use in the retina and optic nerve may be limited by vasoconstrictive effects mediated through Y1 receptor activation. This study evaluated the vascular effects of full-length NPY (1-36) and its N-terminally truncated analog, NPY (3-36), in the mouse retina. Retinal vascular responses were assessed using fluorescein angiography (FFA) after intravitreal administration of different NPY analogs. NPY (1-36) caused transient vasoconstriction via Y1 receptor-mediated calmodulin and pMLC activation. In contrast, NPY (3-36) selectively activates Y2 and Y5 receptors without inducing vasoconstrictive effects. Furthermore, NPY (3-36) through receptor activation preserved retinal ganglion cell density, axonal integrity, and inner retinal function while reducing astrocytic and microglial activation under elevated intraocular pressure. These findings suggest that NPY (3-36) could be a safer therapeutic candidate for glaucoma, highlighting the critical role of receptor-specific modulation to enhance neuroprotection without causing adverse vascular complications.
Indexed as
Identifiers
41460555What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.